August 27, 2026 | Intelligent Commercialization, Pharma, healthcare
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

In our latest series of articles, our experts explore how Intelligent Commercialization™ is helping pharma teams turn insights into action across the lifecycle.
This content was provided by Inizio
Latest Content from Inizio
Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference. In our latest blog post she reflects on the presentations that were given and what lessons can be…
US Director Liza Pliss recently presented the paper ‘Optimize your digital assets with UX research’ at the PMR Conference in New Jersey, USA. Don’t worry if you missed it though,…
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on…
An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at…
In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only…
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
Five new recruits support further growth of the Pharma & Life Sciences team
In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we’ve been using facial analysis to delve further into respondents’ reactions…
Research Partnership launches new patient Living with  Rheumatoid Arthritis (EU & Japan)  2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in…
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1…
